The Shift From 'Good Enough' to True Recovery
A growing chorus of clinicians is challenging the long-standing norm in psychiatric care: accepting partial improvement as a win. A new analysis published in Psychiatric Times (April 2026) highlights how experts are pushing back against the "less bad" mindset in treatment-resistant depression (TRD) — advocating instead for aggressive, patient-centered strategies aimed squarely at full remission.
Treatment-resistant depression, broadly defined as depression that has failed to respond to at least two adequate antidepressant trials, affects an estimated 30% of all patients diagnosed with major depressive disorder. For decades, the standard of care often plateaued at symptom reduction rather than elimination — a benchmark that, the article argues, may actually be doing patients a disservice. Residual symptoms, even mild ones, are strongly associated with relapse, functional impairment, and reduced quality of life.
The piece draws on input from leading psychiatrists who stress that treatment goals must be co-constructed with patients — accounting not just for clinical outcomes but for tolerability, lifestyle impact, and what "better" actually looks like to the individual in front of them.
Where Ketamine Fits in the New TRD Landscape
The renewed emphasis on remission — not just response — puts interventional treatments like low-dose ketamine and its FDA-approved derivative esketamine (Spravato) in a sharper spotlight. Unlike conventional antidepressants, which can take four to eight weeks to demonstrate meaningful effect and frequently require cycling through multiple agents before finding a fit, ketamine operates through an entirely different mechanism: rapid modulation of the glutamate system, promoting synaptic plasticity and neurogenesis in regions of the brain most impacted by chronic depression.
For patients who have exhausted first- and second-line options, this speed and mechanistic novelty aren't trivial advantages — they can be life-altering. Clinical data consistently shows that 50–70% of TRD patients experience significant mood improvement within hours of an initial ketamine infusion, with a meaningful subset achieving full remission after a standard induction series. That kind of outcome is simply not on the table for most patients still cycling through traditional pharmacotherapy.
The Psychiatric Times analysis also underscores something that clinicians in the ketamine space have long understood: side effect profiles and patient priorities must drive treatment sequencing. Ketamine's side effects — dissociation, transient blood pressure changes, the logistical burden of in-office administration — are real considerations. But for a patient who has already endured years of failed trials, weight gain, sexual dysfunction, and emotional blunting from conventional medications, the calculus often tips decisively toward an interventional approach.
Key Takeaway
If your depression hasn't fully resolved after multiple medication trials, partial improvement is not the ceiling. Current clinical guidance supports escalating to interventional options — including ketamine — with the explicit goal of full remission, not just feeling slightly less symptomatic. Advocate for that standard in your own care.
What 'Aggressive Care' Actually Looks Like
The framing of "aggressive" depression care can sound alarming out of context, but what clinicians mean is straightforward: don't linger in treatments that aren't working, set remission as the explicit target from the outset, and layer in augmentation strategies — whether pharmacological, psychotherapeutic, or interventional — without excessive hesitation. The article points to a persistent gap between best-practice guidelines and real-world clinical behavior, where inertia, resource constraints, and low patient expectations conspire to keep people stuck in incomplete recovery.
For patients navigating this system, the implications are practical. First, know that treatment-resistant depression is a recognized clinical category with specialized protocols — you are not simply "hard to treat" or unlikely to get better. Second, if your current provider is not discussing next-step options after two failed trials, it may be time to seek consultation from a psychiatrist with TRD expertise. Third, understand that remission — the absence of depressive symptoms, not just their reduction — is a legitimate and achievable goal, one that research increasingly shows is within reach through the right combination of approaches.
Ketamine-assisted treatment, whether administered as IV infusions or as an FDA-approved nasal spray under supervision, has earned a firm place in evidence-based TRD protocols. As the psychiatric community sharpens its focus on true recovery, the role of rapid-acting, glutamate-targeting interventions is only likely to grow. The conversation is no longer whether these treatments work — it's about making sure patients who need them can actually access them before years of suffering accumulate.
Read the original analysis at Psychiatric Times.
Share